The question whether women and men with acute myocardial infarction (AMI) are treated differently is currently debated. In this analysis we compared pharmacological treatments and revascularization procedures during hospitalization and during 1 year of follow-up in 300 women and 621 men who suffered an AMI in 1986 or 1987 at our hospital. During hospitalization, the mean dose of morphine ( ± SD) during the first 3 days was higher in men compared to women (14.5 ± 15.7 vs. 9.8 ± 10.3 mg, p < 0.001), more men than women were given morphine after the first 24 h (65.4 vs. 49.0%, p < 0.01), and more men were prescribed anticoagulants at discharge (18 vs. 12%, p < 0.05). After 1 year more women than men were on diuretics (61.3 vs. 42.8%, p < 0.001) and a similar observation was made at discharge. This study was performed before thrombolytic therapy was routinely used. The frequency of revascularization procedures did not differ between men and women during hospitalization or during the year of follow-up. In conclusion, no major treatment differences, which could affect the prognosis, were found between women and men hospitalized due to AMI in this study in the prethrombolytic era.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.